[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/27, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)

 [ESMO] 에이비엘, 'CLDN18.2x4-1BB' 위암 1차 3상 "용량확정"
[https://www.biospectator.com/news/view/30192](https://www.biospectator.com/news/view/30192)

 [ESMO] 탱고, 'PRMT5+RAS' 췌장암 2/3차 업데이트 "ORR 82%"
[https://www.biospectator.com/news/view/30184](https://www.biospectator.com/news/view/30184)

 리스큐어, 코스닥 기술성평가 통과.."내년 초 IPO 추진" 
[https://www.biospectator.com/news/view/30198](https://www.biospectator.com/news/view/30198)

 동아ST, '경구 IL-23R' 외용제 제형변경 비임상 "발표"
[https://www.biospectator.com/news/view/30206](https://www.biospectator.com/news/view/30206)

 [ESMO] 큐리언트, 'CDK7 저해제' 고형암 1상 "ESMO 공개"
[https://www.biospectator.com/news/view/30191](https://www.biospectator.com/news/view/30191)

 셀트리온, 3Q 매출 1조5755억·영업이익 5253억 
[https://www.biospectator.com/news/view/30205](https://www.biospectator.com/news/view/30205)

 [ESMO] 삼성에피스, ESMO서 '키트루다 시밀러' 1상 공개
[https://www.biospectator.com/news/view/30208](https://www.biospectator.com/news/view/30208)

 에임드, 베링거 L/O 'ADC' 1상 개시.."마일스톤 수령" 
[https://www.biospectator.com/news/view/30207](https://www.biospectator.com/news/view/30207)

 한미약품, ‘체중관리’ 특화 건기식 ‘에피슬림’ 출시
[https://www.biospectator.com/news/view/30211](https://www.biospectator.com/news/view/30211)

 코오롱생과, '항암바이러스' 대량생산기술 韓·美 특허 
[https://www.biospectator.com/news/view/30209](https://www.biospectator.com/news/view/30209)

 [ESMO] 아케소, 'PD-1xVEGF' 담도암 中3상 SoC比 "OS 25%↑" 
[https://www.biospectator.com/news/view/30182](https://www.biospectator.com/news/view/30182)

 [ESMO] J&J, 할다 ‘AR RIPTAC’ 전립선암 1상 "cORR 69%”
[https://www.biospectator.com/news/view/30190](https://www.biospectator.com/news/view/30190)

 프로앱텍, '이중항체 ADC' 최적화 스캐폴드 2종 "확보" 
[https://www.biospectator.com/news/view/30199](https://www.biospectator.com/news/view/30199)

 씨어스, 카자흐스탄 보건부에 AI 의료 솔루션 소개
[https://www.biospectator.com/news/view/30212](https://www.biospectator.com/news/view/30212)

 에스티팜, 3Q 매출 976억.."전년比 19.1%↑" 
[https://www.biospectator.com/news/view/30216](https://www.biospectator.com/news/view/30216)

 멥스젠, '소량 나노입자 합성 시스템' 출시
[https://www.biospectator.com/news/view/30210](https://www.biospectator.com/news/view/30210)

 동아ST, 3Q 매출 2065억.."전년比 4.1%↑" 
[https://www.biospectator.com/news/view/30215](https://www.biospectator.com/news/view/30215)

 [ESMO] HLB 엘레바, '리픽투·리보세라닙' 임상결과 "ESMO 발표"
[https://www.biospectator.com/news/view/30213](https://www.biospectator.com/news/view/30213)

 GC 이니바이오, '보툴리눔 톡신' 中시판허가
[https://www.biospectator.com/news/view/30217](https://www.biospectator.com/news/view/30217)

[#바이오스펙테이터](?q=%23%EB%B0%94%EC%9D%B4%EC%98%A4%EC%8A%A4%ED%8E%99%ED%85%8C%EC%9D%B4%ED%84%B0) [#전일](?q=%23%EC%A0%84%EC%9D%BC)(10/27, TUE) [#전체기사](?q=%23%EC%A0%84%EC%B2%B4%EA%B8%B0%EC%82%AC)